Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada.

The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we exami...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 32; no. 1; pp. 13 - 40
Main Authors:	Chayab, Lara, Leighl, Natasha B., Tadrous, Mina, Warren, Christine M., Wong, William W. L.
Format:	Journal Article
Published:	MDPI Jan2025
Online Access:	View this record in EBSCOhost